Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.
Join CLL Society and Dr. Deborah Stephens to learn how a comprehensive approach to well-being can complement your CLL care.
As more and more drugs have become available to treat CLL, doctors and patients alike want to know what is the best way to sequence these therapies.
February 2025 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.
January 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
December 2024 CLL Bloodline – Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
One click to our most popular content.
